Below is a list of the treatments we currently offer via our Innovative Medicines Division. Visit Sandoz and Advanced Accelerator Applications to learn about our generics and radiopharmaceutical products.
Please note: Not all treatments are available in all countries.

  • Novartis combination adjuvant therapy Tafinlar® + Mekinist® receives FDA Breakthrough Therapy Designation for stage III BRAF V600 mutation-positive melanoma patients

  • Novartis drug Revolade® shows long-term disease control for chronic/persistent immune thrombocytopenia (ITP)

  • Alcon receives CE Mark for first-of-its-kind AutonoMe(TM) preloaded intraocular lens (IOL) delivery system with Clareon® IOL

  • Alcon introduces new innovations in cataract surgery at European Society of Cataract & Refractive Surgeons 2017 annual congress

  • Novartis and UC Berkeley collaborate to tackle 'undruggable' disease targets

  • Novartis and The Max Foundation transform pioneering cancer access program for people in lower-income countries